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Flat-­‐coated	  retriever	  dogs	  are	  predisposed	  to	  the	  development	  of	  histiocytic	  sarcoma	  (HS),	  a	  poorly	  
differentiated,	  highly	  malignant	  neoplasm.	  We	  have	  previously	  documented	  a	  significant	  lymphocytic	  
infiltrate	  in	  such	  tumors.	  The	  objective	  of	  this	  study	  was	  to	  examine	  the	  presence	  and	  expression	  of	  
regulatory	  T	  cells	  in	  HS	  tumor	  samples.	  Forty	  tumors	  were	  included	  in	  this	  study.	  All	  tumors	  were	  
immunolabelled	  for	  CD3,	  CD79a,	  CD25,	  CD45RA,	  and	  FOXP3.	  The	  proportion	  of	  positive	  cells	  was	  
compared	  between	  tumors	  presenting	  as	  a	  localized	  primary	  soft	  tissue	  mass	  (soft	  tissue	  origin	  HS)	  and	  
disseminated	  HS	  affecting	  viscera,	  especially	  the	  spleen	  (splenic	  origin	  HS).	  By	  immunohistochemistry	  
(IHC),	  95%	  of	  infiltrating	  T	  cells	  were	  positive	  for	  FOXP3	  in	  all	  sections	  suggesting	  the	  presence	  of	  
regulatory	  T	  cells.	  The	  proportion	  of	  cells	  positive	  for	  FOXP3	  was	  higher	  in	  the	  tumors	  arising	  in	  soft	  
tissues	  whilst	  the	  proportion	  of	  CD45RA-­‐positive	  cells	  was	  higher	  in	  the	  splenic	  origin	  HS.	  Canine	  HS	  has	  
an	  aggressive	  clinical	  behavior	  and	  is	  uniformly	  fatal.	  The	  difference	  in	  proportion	  of	  tumor-­‐infiltrating	  
lymphocytes	  positive	  for	  these	  two	  markers	  in	  the	  two	  locations	  may	  represent	  differences	  in	  tumor	  
microenvironment	  between	  the	  two	  sites.	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Introduction	  
Histiocytic	  proliferative	  disorders	  are	  prevalent	  in	  dogs	  and	  represent	  a	  variety	  of	  clinical	  and	  pathologic	  
presentations	  with	  recognized	  breed	  predispositions.	  We	  have	  previously	  documented	  that	  HS	  accounts	  
for	  25	  %	  of	  all	  neoplasms	  affecting	  the	  Flat-­‐coated	  retriever	  and	  up	  to	  50	  %	  of	  malignant	  neoplasms	  in	  this	  
breed,3,	  9	  where	  it	  presents	  with	  predominantly	  localized	  lesions	  but	  with	  a	  high	  metastatic	  rate.13,	  20,	  21	  	  
	  
Histiocytic	  sarcomas	  are	  most	  often	  derived	  from	  cells	  with	  the	  phenotypic	  profile	  of	  interstitial	  dendritic	  
cells	  (DCs).	  These	  cells	  occur	  almost	  in	  all	  tissues	  except	  the	  brain,	  and	  therefore	  HS	  arise	  in	  almost	  any	  
part	  of	  the	  body.	  Interstitial	  DCs	  are	  identifiable	  in	  tissues	  by	  immunophenotyping	  and	  they	  are	  positive	  
to	  CD1a,	  CD11c,	  CD11b,	  and	  MHC	  class	  II.	  9,	  20,	  21	  Most	  reports	  of	  HS	  in	  the	  Flat-­‐coated	  retriever	  describe	  a	  
localized	  form,	  arising	  within	  the	  musculature	  or	  fascia	  (including	  periarticular)	  of	  limbs.	  A	  disseminated,	  
visceral	  form	  often	  affecting	  the	  spleen	  also	  occurs	  in	  the	  breed	  but	  is	  less	  common.9,	  20	  In	  the	  Flat-­‐coated	  
retriever,	  localized	  HS	  are	  highly	  malignant	  neoplasms,	  metastasis	  is	  initially	  via	  lymphatics	  to	  the	  loco-­‐
regional	  lymph	  nodes.	  Distant	  metastases,	  involving	  spleen,	  lungs,	  liver,	  bone	  marrow,	  subcutaneous	  
tissue,	  bone,	  skeletal	  muscle,	  kidney,	  and	  central	  nervous	  system	  have	  also	  been	  reported,	  which	  
confounds	  distinction	  between	  the	  two	  forms	  of	  the	  disease.3,	  14,	  20	  HS	  is	  not	  exclusive	  to	  Flat-­‐coated	  
retrievers;	  other	  breeds	  of	  dogs	  where	  HS	  has	  been	  reported	  include	  Bernese	  Mountain	  dogs,	  
Rottweilers,	  and	  Golden	  retrievers.	  We	  have	  previously	  documented	  a	  10-­‐20	  %	  lymphocytic	  infiltrate	  in	  
localized	  and	  visceral	  HS	  of	  Flat-­‐coated	  retrievers	  and	  shown	  these	  to	  be	  T	  lymphocytes,	  suggesting	  a	  cell-­‐
mediated	  immune	  response.9,	  21	  	  
	  
The	  host’s	  immune	  system	  reacts	  to	  tumors	  via	  adaptive	  responses	  directed	  mainly	  towards	  tumor	  
associated	  antigens	  (TAA).12	  However,	  there	  are	  mechanisms	  enabling	  the	  tumor	  to	  escape	  from	  or	  evade	  
immune	  surveillance,	  one	  of	  which	  is	  suppression	  of	  the	  T	  cell-­‐mediated	  anti-­‐tumor	  response.	  This	  may	  be	  
mediated	  by	  induction	  of	  regulatory	  T	  cells	  (Tregs).29	  In	  most	  human	  tumors,	  the	  majority	  of	  tumor-­‐
infiltrating	  lymphocytes	  are	  CD3+	  cells	  which	  include	  CD8+	  cytotoxic	  cells,	  CD4+	  helper	  cells,	  and	  CD4+	  
regulatory	  cells	  (previously	  known	  as	  suppressor	  T	  cells).22	  The	  presence	  of	  tumor	  infiltrating	  lymphocytes	  
expressing	  CD8	  is	  usually	  associated	  with	  better	  prognosis,	  whereas	  infiltration	  of	  lymphocytes	  positive	  
for	  regulatory	  markers	  is	  mostly	  associated	  with	  a	  worse	  prognosis.11	  	  
	  
The	  X	  chromosome-­‐encoded,	  intracellular	  forkhead	  transcription	  factor,	  forkhead	  box	  P3	  (FOXP3)	  
transcription	  factor	  was	  identified	  as	  an	  essential	  factor	  for	  the	  suppressive	  phenotype	  of	  natural	  Tregs	  
and	  is	  a	  highly	  specific	  marker	  of	  murine	  Tregs.	  FOXP3	  is	  also	  stably	  up-­‐regulated	  in	  human	  Tregs.15,	  30	  	  
	  
There	  is	  an	  intense	  interest	  in	  the	  role	  of	  Tregs	  in	  human	  and	  animal	  cancer.6,7	  Increased	  numbers	  of	  
CD4+CD25+FOXP3+	  Tregs	  have	  been	  observed	  in	  peripheral	  blood,	  lymph	  nodes,	  and	  various	  neoplasms	  
in	  human	  cancer	  patients	  and	  are	  usually	  associated	  with	  poor	  prognosis.5,	  7,	  10,	  24,	  28,	  31	  However	  some	  
studies	  have	  found	  no	  prognostic	  value	  and	  in	  others	  the	  presence	  of	  FOXP3+Treg	  in	  neoplasms	  has	  been	  
correlated	  with	  a	  more	  favourable	  prognosis.8,	  17	  The	  presence	  of	  Tregs	  in	  healthy	  and	  cancer-­‐bearing	  
dogs	  has	  been	  documented;	  dogs	  with	  melanoma,	  osteosarcoma,	  mammary	  gland	  adenocarcinoma,	  and	  
lymphoma	  have	  been	  shown	  to	  have	  increased	  numbers	  of	  Tregs	  in	  their	  peripheral	  blood.7,	  24,	  28	  The	  
presence	  of	  Tregs	  has	  also	  been	  investigated	  in	  canine	  tumor	  tissue.19,	  23	  The	  number	  of	  Tregs	  within	  
canine	  neoplasms	  is	  significantly	  increased	  compared	  with	  Tregs	  in	  peripheral	  blood	  of	  dogs	  with	  cancer,	  
suggesting	  that	  the	  presence	  of	  neoplastic	  cells	  induces	  either	  local	  proliferation	  or	  selective	  migration	  of	  
Tregs	  to	  tumor-­‐infiltrated	  sites.23	  Canine	  CD4+FOXP3+	  Tregs	  show	  increased	  production	  of	  IL-­‐10	  and	  TGF-­‐
beta,	  which	  confirms	  their	  immunosuppressive	  function	  but	  studies	  of	  the	  prognostic	  implications	  of	  
canine	  Tregs	  are	  still	  limited.2	  	  
	  
The	  purpose	  of	  this	  work	  was	  to	  establish	  what	  proportion	  of	  the	  previously	  documented	  lymphocytic	  
infiltrate	  in	  soft	  tissue	  and	  splenic	  HS	  of	  Flat-­‐coated	  retriever	  dogs	  comprise	  regulatory	  T	  cells,	  to	  serve	  as	  
basis	  for	  future	  studies	  assessing	  correlation	  between	  Tregs	  and	  prognosis	  for	  Flat-­‐coated	  retrieves	  with	  
HS.	  	  
	  
Materials	  and	  Methods	  	  
	  
The	  tumor	  sections	  selected	  for	  this	  study	  were	  from	  the	  forty	  HS	  samples	  previously	  reported	  by	  
Constantino-­‐Casas	  et	  al.	  (2011).9	  For	  IHC,	  3	  µm	  serial	  sections	  were	  cut	  from	  the	  appropriate	  paraffin	  
blocks	  and	  mounted	  on	  positively	  charged	  slides	  (Snowcoat;	  Surgipath	  Europe	  Ltd,	  UK).	  Sections	  were	  
dried	  overnight	  at	  50	  °C	  before	  automated	  processing	  using	  the	  PT	  link	  instrument	  Envision	  Flex	  antigen	  
retrieval	  solution,	  high	  pH	  (Dako	  Carpinteria,	  CA,	  USA).	  This	  allowed	  for	  deparaffinization,	  rehydration,	  
and	  antigen	  retrieval	  in	  a	  combined	  3-­‐in-­‐1	  procedure.	  Sections	  were	  immersed	  in	  the	  pre-­‐heated	  working	  
solution	  (pH	  9.0).	  Once	  the	  temperature	  had	  reached	  97	  °C,	  sections	  were	  incubated	  for	  20	  minutes,	  left	  
to	  cool	  to	  65	  °C	  and	  immediately	  rinsed	  in	  buffer	  (Dako	  Envision	  wash	  buffer)	  at	  room	  temperature.	  An	  
automated	  IHC	  system	  (Dako	  Autostainer,	  Dako,	  Carpineteria,	  CA)	  was	  used	  to	  process	  the	  prepared	  
tissues.	  Endogenous	  peroxidise	  activity	  was	  inhibited	  using	  Dako	  REAL	  peroxidise-­‐blocking	  solution.	  The	  
immunohistochemical	  antibodies	  were	  anti-­‐CD3	  (mouse	  anti-­‐human	  monoclonal,	  1:150,	  clone	  F7-­‐2-­‐38	  
Dako,	  UK),	  anti-­‐CD79a	  (mouse	  anti-­‐human	  monoclonal,	  1:400,	  clone	  HM57,	  Dako,	  UK),	  anti-­‐CD25	  (mouse	  
anti-­‐human	  monoclonal,	  1:100,	  clone	  NCL-­‐CD25-­‐305,	  Leica/NOVACASTRA,	  UK),	  anti-­‐CD45RA	  (mouse	  anti-­‐
canine	  monoclonal,	  1:50,	  clone	  CA21-­‐4B3-­‐IgG1,	  US	  Davis,	  USA),	  anti-­‐FOXP3	  (rabbit	  anti-­‐human	  polyclonal,	  
1:500,	  ref.	  Rb	  anti-­‐foxP3,	  lot	  121220CF	  Insight	  Biotech,	  UK).	  Peroxidase	  activity	  was	  demonstrated	  using	  
3,3’-­‐diaminobenzidine	  (DAB)	  solution	  for	  10	  minutes,	  and	  slides	  were	  counterlabelled	  with	  Gill’s	  
hematoxylin	  for	  2	  minutes	  before	  rinsing,	  dehydrating,	  clearing,	  and	  mounting	  with	  coverslips.	  Labelling	  
with	  antibodies	  anti-­‐CD25	  and	  anti-­‐FOXP3	  were	  performed	  on	  consecutive	  slides.	  Double	  IHC	  was	  not	  
performed	  however	  consecutive	  slides	  were	  used	  and	  the	  same	  areas	  of	  each	  section	  were	  examined.	  A	  
semi-­‐quantitative	  analysis	  of	  immunolabelling	  was	  performed	  as	  previously	  described	  by	  Constantino-­‐
Casas	  et	  al.9	  Positive	  control	  tissues	  included	  reactive	  dog	  lymph	  node	  or	  dog	  tonsil.	  Antibody	  diluent	  
(Dako)	  was	  used	  in	  place	  of	  the	  primary	  antibody	  to	  act	  as	  a	  negative	  control	  in	  each	  immunolabelling	  
procedure.	  In	  addition	  many	  of	  the	  tumor	  sections	  acted	  as	  internal	  positive	  and	  negative	  controls	  for	  the	  
antibodies.	  Immunolabelling	  within	  tumors	  was	  assessed	  as	  positive	  or	  negative.	  Six	  slides	  per	  case	  were	  
examined.	  Slides	  were	  initially	  examined	  at	  low	  magnification	  (x20)	  to	  confirm	  the	  presence	  of	  positive	  
immunolabelling	  of	  lymphocytes	  within	  the	  neoplastic	  tissue.	  Detailed	  examination	  of	  selected	  regions	  
was	  then	  carried	  out	  using	  forty	  times	  magnification	  and	  followed	  the	  pattern:	  left	  (field	  2),	  left	  (field	  3),	  
down	  (field	  4),	  and	  right	  (field	  5)	  equating	  5	  fields	  per	  slide.	  The	  periphery	  of	  the	  section	  was	  excluded	  to	  
avoid	  cutting	  artefacts	  and	  precipitated	  DAB.	  If	  necrosis,	  haemorrhage	  or	  artefacts	  were	  present	  in	  over	  
10	  %	  of	  the	  field,	  the	  cells	  were	  not	  counted,	  and	  the	  field	  was	  moved	  to	  the	  left.	  If	  this	  continued	  or	  the	  
edge	  of	  the	  slide	  was	  reached,	  it	  was	  moved	  down.	  This	  was	  repeated	  until	  a	  full,	  countable	  field	  was	  
reached.	  The	  percentage	  of	  labelled	  lymphocytes	  was	  obtained	  by	  counting	  the	  number	  of	  
immunolabelled	  cells	  and	  number	  of	  lymphocyte	  nuclei	  (as	  a	  measure	  of	  total	  cells)	  per	  field	  and	  
calculating	  the	  percentage	  of	  labelled	  in	  total	  cells.	  The	  average	  was	  calculated	  for	  percentage	  of	  labelling	  
for	  each	  slide.	  	  
	  
Statistical	  analysis	  was	  performed	  using	  SPSS	  -­‐Version	  20.0	  (Armonk,	  NY).	  Data	  were	  assessed	  for	  
normality	  by	  use	  of	  the	  Shapiro-­‐Wilk	  test,	  which	  demonstrated	  that	  data	  for	  all	  markers	  assessed	  was	  not	  
normally	  distributed	  (P>0.05).	  Median,	  25th	  and	  75th	  percentiles	  of	  cells	  that	  were	  positive	  for	  the	  
various	  markers	  in	  each	  group	  were	  calculated.	  The	  Mann	  Whitney	  U	  test	  was	  used	  to	  compare	  the	  
percentage	  of	  positive	  cells	  between	  the	  two	  groups.	  A	  p	  value	  of	  <0.05	  was	  considered	  statistically	  




As	  previously	  described,9	  of	  the	  40	  HS	  from	  Flat-­‐coated	  retrievers,	  20	  were	  of	  splenic	  origin	  and	  20	  were	  
from	  primary	  soft	  tissue	  neoplasms.	  There	  were	  22	  females	  and	  18	  males	  and	  the	  median	  age	  of	  affected	  
dogs	  was	  8.4	  years	  (range	  from	  5	  to	  11.8	  years	  old).	  There	  was	  no	  difference	  in	  age	  or	  sex	  distribution	  
between	  the	  soft	  tissue	  and	  splenic	  origin	  HS.	  Clinical-­‐pathological	  data	  was	  available	  for	  all	  dogs,	  with	  
follow	  up	  information	  available	  for	  32/40	  of	  the	  cases	  (80	  %);	  8	  dogs	  (20	  %;	  3	  from	  the	  splenic	  group	  and	  5	  
from	  the	  soft	  tissue	  group)	  were	  lost	  to	  follow	  up	  (Supplemental	  Material).	  	  
	  
The	  main	  presenting	  sign	  in	  the	  20	  dogs	  with	  splenic	  HS	  was	  a	  palpable	  abdominal	  mass	  (11),	  lethargy	  (9),	  
severe	  anaemia	  (8),	  weight	  loss	  (6),	  and	  exercise	  intolerance	  (4).	  Less	  common	  findings	  recorded	  were:	  
inappetence	  (3),	  pyrexia	  (2),	  vomiting	  (2),	  hypoalbuminaemia	  (2),	  polydipsia/polyuria	  (2),	  regurgitation	  
(1),	  melena	  (1),	  neutropenia	  (1),	  thrombocytopenia	  (1),	  elevation	  in	  serum	  levels	  of	  liver	  enzymes	  (1),	  
collapse	  (1),	  and	  pallor	  (1).	  None	  of	  these	  dogs	  presented	  with	  a	  detectable	  peripheral	  mass,	  primary	  limb	  
tumour	  or	  history	  of	  lameness.	  Out	  of	  20	  dogs	  with	  splenic	  HS,	  13	  had	  exploratory	  laparotomy	  and	  of	  
these,	  6	  dogs	  had	  documented	  splenectomy,	  two	  were	  treated	  with	  chemotherapy	  (1	  with	  vincristine,	  the	  
other	  with	  lomustine).	  One	  dog	  received	  a	  whole	  blood	  transfusion	  due	  to	  severe	  anaemia.	  Information	  
regarding	  treatment	  was	  not	  available	  for	  one	  dog	  (lost	  to	  follow	  up).	  All	  of	  the	  dogs	  from	  this	  group	  were	  
euthanized	  either	  at	  the	  time	  of	  diagnosis	  (6/20),	  at	  the	  time	  of	  exploratory	  laparotomy	  (4/20)	  or	  within	  
120	  days	  of	  diagnosis	  (7/20).	  Three	  dogs	  were	  lost	  to	  follow	  up.	  One	  dog	  that	  was	  diagnosed	  with	  an	  
abdominal	  mass	  during	  routine	  consultation	  underwent	  splenectomy	  and	  lived	  for	  14	  months,	  after	  which	  
time	  he	  developed	  a	  quadriplegia	  and	  was	  suspected	  to	  have	  spinal	  metastases.	  	  
	  
All	  20	  dogs	  with	  soft	  tissue	  HS	  presented	  with	  a	  solitary	  mass,	  9/20	  dogs	  presented	  with	  lameness.	  Twelve	  
tumors	  presented	  in	  the	  front	  limb,	  6	  in	  the	  rear	  leg,	  one	  dog	  presented	  with	  a	  mass	  in	  the	  neck	  and	  one	  
on	  the	  flank.	  Eight	  of	  the	  20	  dogs	  were	  euthanized	  at	  the	  time	  of	  the	  diagnosis.	  Six	  dogs	  (6)	  were	  
euthanized	  between	  5-­‐730	  days	  after	  diagnosis,	  six	  dogs	  (6)	  were	  lost	  to	  follow	  up.	  Of	  the	  20	  dogs,	  7	  were	  
treated	  with	  surgical	  excision/cytoreductive	  surgery,	  10	  were	  not	  treated,	  and	  2	  received	  a	  course	  of	  
hypofractionated	  radiotherapy	  (4x850cGy).	  One	  of	  these	  dogs	  was	  also	  treated	  with	  one	  dose	  of	  adjuvant	  
chemotherapy	  (lomustine)	  and	  the	  other	  dog	  underwent	  surgical	  excision	  of	  the	  tumor	  (this	  dog	  was	  one	  
of	  the	  seven	  dogs	  undergoing	  a	  surgical	  procedure).	  Treatment	  was	  not	  recorded	  for	  one	  dog	  which	  was	  
one	  of	  the	  dogs	  lost	  to	  follow	  up.	  Biopsy	  samples	  were	  obtained	  from	  4	  of	  20	  dogs	  with	  the	  remaining	  16	  
dogs	  having	  their	  samples	  collected	  at	  post	  mortem	  examination.	  Four	  dogs	  (3	  front	  limb,	  1	  hind	  limb	  HS)	  
had	  an	  apparent	  longer	  survival	  (365-­‐1095	  days)	  compared	  to	  the	  remaining	  dogs	  in	  this	  group.	  Three	  of	  
them	  (two	  fore	  and	  one	  hind	  limb	  HS)	  were	  treated	  with	  surgery	  (limb	  amputation),	  one	  dog	  was	  treated	  
with	  radiation	  therapy	  and	  lomustine.	  	  
	  
For	  all	  antibodies,	  immunopositive	  labelling	  was	  present	  in	  the	  positive	  control	  sections	  but	  not	  detected	  
in	  the	  negative	  controls.	  Despite	  the	  variable	  neoplasm	  morphology	  and	  different	  locations,	  all	  forty	  
tumors	  contained	  lymphocytes	  expressing	  CD3	  and	  CD45RA	  scattered	  through	  the	  neoplastic	  tissues,	  
including	  the	  periphery	  of	  the	  neoplasm.	  CD45RA	  labelling	  was	  membranous	  and	  CD3	  labelling	  was	  both	  
membranous	  and	  cytoplasmic	  (Figures	  1	  &	  2).	  FOXP3	  labelling	  was	  nuclear.	  In	  all	  tumor	  sections	  
examined,	  FOXP3	  positive	  cells	  were	  present	  and	  scattered	  between	  the	  neoplastic	  cells,	  with	  over	  95	  %	  
of	  CD3-­‐positive	  cells	  being	  FOXP3+	  (Figures	  3	  &	  4).	  IHC	  data	  for	  CD3,	  CD25,	  CD45RA,	  CD79a,	  and	  FOXP3	  is	  
summarized	  in	  Table	  1.	  	  
	  CD25	  labelling	  was	  membranous	  and	  the	  location	  of	  CD25-­‐positive	  cells	  was	  similar	  to	  FOXP3-­‐positive	  
cells	  (data	  not	  shown).	  	  
	  
When	  the	  proportion	  of	  cells	  positive	  for	  CD3,	  CD79a,	  CD25,	  CD45RA,	  and	  FOXP3	  were	  compared	  
between	  neoplasms	  at	  the	  different	  sites,	  significant	  differences	  were	  identified	  in	  the	  proportion	  of	  
FOXP3-­‐	  and	  CD45RA-­‐positive	  cells	  between	  the	  sites.	  The	  proportion	  of	  cells	  positive	  for	  CD45RA	  was	  
significantly	  higher	  in	  splenic	  HS	  compared	  with	  soft	  tissue	  origin	  HS	  (7	  %	  vs.	  0	  %;	  p<0.001)	  (Figure	  5)	  
whereas	  the	  proportion	  of	  cells	  positive	  for	  FOXP3	  was	  significantly	  higher	  in	  soft	  tissue	  tumors	  compared	  
with	  splenic	  HS	  (19	  %	  vs.	  1	  %;	  p=0.019)	  (Figure	  6).	  There	  were	  no	  differences	  in	  the	  expression	  levels	  of	  




The	  purpose	  of	  this	  study	  was	  to	  establish	  what	  proportion	  of	  the	  previously	  documented	  lymphocytic	  
infiltrate	  in	  soft	  tissue	  and	  splenic	  HS	  of	  Flat-­‐coated	  retriever	  dogs	  comprise	  regulatory	  T	  cells,	  to	  serve	  as	  
basis	  for	  future	  studies	  to	  assess	  correlation	  between	  Tregs	  and	  prognosis	  for	  Flat-­‐coated	  retrievers	  with	  
HS.	  	  
	  
The	  tumor	  samples	  selected	  for	  this	  study	  represented	  both	  the	  soft	  tissue	  (n	  =	  20)	  and	  splenic	  (n=20)	  
variants	  of	  HS	  from	  Flat-­‐coated	  retrievers.	  The	  splenic	  neoplasms	  were	  frequently	  associated	  with	  severe	  
systemic	  signs,	  particularly	  anaemia	  (8/20	  cases).	  It	  has	  been	  documented	  13	  that	  anaemia	  in	  affected	  
dogs,	  may	  be	  due	  to	  an	  haemophagocytic	  variant	  of	  HS,	  often	  associated	  with	  a	  paraneoplastic	  
hypoalbuminaemia.	  27	  The	  severity	  of	  the	  clinical	  signs	  and	  /	  or	  presence	  of	  widespread	  visceral	  
metastases	  at	  the	  time	  of	  diagnosis	  (often	  documented	  at	  the	  time	  of	  exploratory	  laparotomy),	  led	  to	  
most	  of	  these	  dogs	  being	  euthanized	  immediately	  following	  diagnosis.	  Hence	  the	  prognosis	  for	  this	  group	  
of	  dogs	  was	  universally	  poor.	  In	  only	  one	  dog	  was	  a	  splenic	  mass	  noted	  during	  routine	  examination;	  this	  
dog	  underwent	  splenectomy	  and	  survived	  a	  further	  14	  months.	  This	  may	  provide	  some	  justification	  for	  
routine	  screening	  of	  dogs	  over	  7	  years	  of	  age.	  	  
	  
The	  dogs	  with	  the	  soft	  tissue	  form	  of	  the	  disease,	  all	  of	  which	  presented	  with	  a	  solitary	  mass,	  had	  a	  
marginally	  better	  prognosis	  than	  those	  with	  splenic	  neoplasms.	  However,	  even	  in	  this	  group	  survival	  times	  
were	  poor	  with	  13/20	  being	  euthanized	  at	  or	  within	  6	  months	  of	  diagnosis	  due	  to	  the	  extent	  of	  the	  
primary	  neoplasms	  and	  its	  rapid	  and	  often	  painful	  progression.	  In	  those	  dogs	  where	  treatment	  was	  
attempted,	  survival	  was	  still	  poor	  and	  did	  not	  exceed	  6	  months	  in	  most	  cases.	  This	  is	  consistent	  with	  
previously	  reported	  survival	  times	  (median	  167	  days)	  for	  dogs	  receiving	  any	  kind	  of	  chemotherapy,	  
radiotherapy,	  surgery	  or	  any	  combination.	  14	  However,	  there	  were	  4	  long-­‐term	  survivors	  in	  this	  group	  
living	  up	  to	  1095	  days,	  which	  supports	  the	  suggestion	  that	  the	  localised	  form	  of	  HS	  may	  have	  a	  better	  
prognosis	  than	  the	  splenic	  /	  disseminated	  form.	  Two	  reports	  have	  recently	  suggested	  that	  dogs	  with	  the	  
localized	  form	  of	  HS,	  with	  no	  evidence	  of	  metastasis	  at	  presentation,	  treated	  with	  aggressive	  local	  therapy	  
and/or	  chemotherapy,	  can	  achieve	  longer	  survival	  times:	  980	  days	  and	  568	  days,	  respectively.18,	  26	  
However	  only	  2/19	  reported	  by	  Klahn	  et	  al.18	  and	  none	  of	  the	  16	  dogs	  reported	  in	  Skorupski	  et	  al.26	  were	  
Flat-­‐coated	  retrievers.	  	  
	  
We	  have	  previously	  documented	  a	  high	  proportion	  (10	  –	  20	  %)	  of	  infiltrating	  T	  cells	  in	  both	  splenic	  and	  
soft	  tissue	  HS	  from	  Flat-­‐coated	  retrievers.	  The	  present	  study	  has	  demonstrated	  that	  the	  majority	  of	  these	  
tumor-­‐infiltrating	  lymphocytes	  are	  FOXP3-­‐positive	  suggesting	  them	  to	  be	  regulatory	  T	  cells.9	  	  
	  
In	  dogs,	  HSs	  arise	  from	  interstitial	  DCs	  that	  occur	  in	  most	  tissues	  of	  the	  body	  (except	  the	  brain)	  and	  these	  
cells	  are	  potent	  antigen	  presenting	  cells.	  	  
	  
It	  is	  known	  that	  dendritic	  cells	  play	  a	  pivotal	  role	  in	  determining	  tolerance	  versus	  immunity,	  so	  
determining	  the	  nature	  of	  the	  infiltrating	  T	  cells	  seemed	  a	  key	  step	  in	  better	  understanding	  the	  
relationship	  between	  the	  neoplasm,	  its	  microenvironment,	  and	  the	  immune	  system.	  The	  finding	  that	  the	  
majority	  of	  infiltrating	  T	  cells	  expressed	  FOXP3,	  suggesting	  them	  to	  be	  regulatory	  T	  cells,	  raises	  interesting	  
questions	  of	  cause	  and	  effect,	  and	  whether	  there	  is	  a	  correlation	  between	  high	  numbers	  of	  FOXP3	  
positive	  cells	  and	  prognosis,	  which	  lie	  beyond	  the	  remit	  of	  the	  present	  study,	  but	  could	  direct	  future	  
studies.	  	  
	  
The	  proportion	  of	  cells	  labelling	  positive	  for	  FOXP3	  was	  higher	  in	  the	  soft	  tissue	  form	  compared	  to	  the	  
splenic	  form	  of	  HS.	  This	  may	  reflect	  the	  different	  microenvironment	  provided	  by	  a	  soft	  tissue	  versus	  
splenic	  site	  of	  origin.	  A	  recent	  study	  has	  suggested	  that	  hypoxia	  in	  canine	  neoplasms	  may	  result	  in	  an	  
increased	  infiltration	  by	  Tregs.16	  We	  have	  previously	  demonstrated	  that	  HSs	  show	  higher	  Glut-­‐1	  
immunoreactivity	  and	  angiogenesis	  than	  low	  grade	  soft	  tissue	  sarcomas,	  suggesting	  that	  hypoxia	  plays	  an	  
important	  role	  in	  the	  biology	  of	  these	  neoplasms.1	  	  
	  
Whilst	  it	  has	  been	  well	  documented	  that	  an	  increased	  number	  of	  regulatory	  T	  cells	  in	  human	  patients	  with	  
diverse	  solid	  neoplasms	  and	  haematological	  malignancies	  can	  be	  a	  positive	  prognostic	  factor,	  studies	  on	  
Tregs	  and	  FOXP3-­‐positive	  cells	  in	  canine	  solid	  neoplasms,	  although	  limited,	  all	  report	  increased	  numbers	  
of	  Tregs	  as	  a	  negative	  prognostic	  factor.4,	  9	  	  
	  
In	  the	  present	  study,	  the	  soft	  tissue	  form	  of	  HS	  showed	  a	  higher	  proportion	  of	  FOXP3	  cells,	  which	  is	  
interesting	  as	  this	  form	  of	  HS	  has	  been	  demonstrated	  to	  carry	  a	  marginally	  improved	  prognosis	  when	  
compared	  to	  the	  disseminated	  form,	  even	  though	  both	  variants	  are	  highly	  malignant.3	  Too	  few	  cases	  in	  
this	  study	  received	  any	  form	  of	  treatment	  to	  allow	  a	  meaningful	  assessment	  of	  the	  prognostic	  significance	  
of	  the	  proportion	  of	  cells	  labelling	  positive	  for	  FOXP3	  and	  further	  studies	  are	  warranted.	  	  
	  
The	  proportion	  of	  FOXP3	  and	  CD45RA	  positive	  cells	  differed	  between	  splenic	  and	  soft	  tissue	  neoplasms.	  
CD45RA	  is	  a	  marker	  for	  naòve	  T	  cells	  but	  is	  also	  a	  common	  marker	  for	  haematopoietic	  cells	  except	  
erythrocytes	  and	  platelets.25	  It	  detects	  basophils,	  granulocytes,	  lymphocytes,	  macrophages/histiocytes,	  
mast	  cells,	  monocytes,	  and	  plasma	  cells.25	  The	  higher	  proportion	  of	  cells	  positive	  for	  CD45RA	  in	  splenic	  
compared	  to	  soft	  tissue	  HS	  can	  be	  explained	  by	  a	  more	  heterogenous	  haematopoietic	  cell	  population	  in	  
the	  canine	  spleen	  where	  erythrocytes,	  granulocytes,	  and	  circulating	  mononuclear	  cells	  are	  commonly	  
seen.	  	  
	  
A	  limitation	  to	  this	  work	  is	  that	  some	  animals	  were	  lost	  to	  follow	  up	  and	  some	  information	  was	  not	  
available.	  The	  sample	  size	  for	  both	  groups	  was	  relatively	  small,	  which	  limited	  the	  statistical	  power	  of	  the	  
study.	  The	  use	  of	  formalin-­‐fixed	  paraffin-­‐embedded	  tissues	  limited	  the	  range	  of	  antibodies	  available	  for	  
IHC,	  particularly	  with	  respect	  to	  CD4	  and	  CD8.	  	  
	  
This	  work	  demonstrated	  the	  presence	  of	  FOXP3-­‐positive	  cells	  which	  are	  most	  likely	  regulatory	  T	  cells	  in	  
the	  localized	  and	  disseminated	  forms	  of	  HSs	  of	  Flat-­‐coated	  retrievers,	  and	  showed	  a	  lower	  percentage	  of	  
FOXP3	  and	  higher	  percentage	  of	  CD45RA	  expressing	  cells	  in	  splenic	  compared	  to	  soft	  tissue	  HS	  of	  Flat	  
coated	  retriever	  dogs.	  These	  findings	  are	  a	  first	  step	  in	  the	  evaluation	  of	  tumor-­‐infiltrating	  lymphocytes	  in	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Figure	  legends	  	  
	  
Figures	  1-­‐4.	  Histiocytic	  sarcomas:	  spleen	  (Figure	  1),	  subcutaneous	  tissue	  (Figure	  2-­‐4),	  dog,	  
immunohistochemistry;	  3,3’-­‐diaminobenzidine	  chromogen.	  Figure	  1.	  IHC	  for	  CD45RA-­‐positive	  cells	  
characterized	  by	  their	  membranous	  labelling.	  Figure	  2.	  IHC	  for	  CD3-­‐positive	  cells	  characterized	  by	  their	  
membranous	  and	  cytoplasmic	  labelling.	  Figure	  3.	  IHC	  demonstrating	  a	  strong	  FOXP3-­‐positive	  nuclear	  
labelling	  of	  cells.	  Figure	  4.	  IHC	  demonstrating	  a	  weak	  FOXP3-­‐positive	  nuclear	  labelling	  of	  cells.	  	  
	  
Figure	  5.	  Scatter	  plot	  showing	  the	  percentage	  of	  CD45RA-­‐positive	  lymphocytes	  is	  higher	  in	  visceral	  
compared	  to	  soft	  tissue	  HS.	  The	  line	  represents	  the	  median	  value	  for	  each	  group	  **:	  p<0.001.	  	  
	  
Figure	  6.	  Scatter	  plot	  showing	  the	  percentage	  of	  FOXP3-­‐positive	  lymphocytes	  is	  lower	  in	  visceral	  
compared	  to	  soft	  tissue	  HS.	  The	  line	  represents	  the	  median	  value	  for	  each	  group.	  *:	  p=0.019.	  	  
Table	  1.	  Comparison	  of	  immunohistochemical	  findings	  in	  20	  visceral	  and	  20	  soft	  tissue	  histiocytic	  
sarcomas	  of	  dogs.	  The	  data	  show	  the	  median	  percentage	  (and	  25th,	  75th	  percentiles)	  of	  cells	  that	  are	  
labelled	  for	  each	  marker.	  	  
	  
Marker	   %	  positive	  cells	  
seen	  
Median	  [25th,	  75th	  
percentiles]	  
%	  positive	  cells	  in	  
visceral	  tumours	  
Median	  [25th,	  75th	  
percentiles]	  
%	  positive	  cells	  in	  soft	  
tissue	  tumours	  
Median	  [25th,	  75th	  
percentiles]	  
P	  value	  
CD3	   16	  [10,	  28]	   18	  [9,	  35]	   16	  [10,	  23]	   0.523	  
CD25	   5	  [1,	  24]	   3	  [0,	  26]	   6	  [2,	  25]	   0.382	  
CD45RA	   3	  [0,	  15]	   7	  [3,	  20]	   0	  [0,	  3]	   <0.001	  
CD79a	   0	  [0,	  8]	   1	  [0,	  10]	   0	  [0,	  3]	   0.498	  
FOXP3	   7	  [1,	  20]	   1	  [0,	  10]	   19	  [5,	  30]	   0.019	  
 
	  
Figure	  1-­‐4	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
Figure	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